NCT00409578 / 2006-001763-36: Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary Syndrome |
|
|
| Completed | 2 | 1101 | US, Canada, Europe, RoW | Placebo, Aliskiren 300 mg, Valsartan 320 mg, Aliskiren/valsartan 300/320 mg | Novartis, The TIMI Study Group | Post Acute Coronary Syndrome, Myocardial Ischemia | 04/09 | 04/09 | | |
